



Used in Lieu of PTO/SB/08A/B
(Based on PTO 04-07 version)

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	10/714,353-Conf. #6363
				Filing Date	November 14, 2003
				First Named Inventor	Janine SCHUURMAN
				Art Unit	1643
				Examiner Name	L. A. Bristol
Sheet	1	of	1	Attorney Docket Number	GMI-059

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (If known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ²
		Country Code ³ -Number ⁴ -Kind Code ⁵ (If known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
LAB	C1	Green, Larry L., "Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies," <i>Journal of Immunological Methods</i> , Vol. 231:11-23 (1999)		
	C2	Henry, Mitchell L. et al., "The use of basiliximab in solid organ transplantation," <i>Expert Opin. Pharmacother.</i> , Vol. 3(10):1657-1663 (2002)		
	C3	Östberg, L. et al., "Human and humanized monoclonal antibodies: preclinical studies and clinical experience," <i>Biochemical Society Transactions</i> , Vol. 23(4):1038-1043 (1995)		
	C4	Pascual, Julio et al., "Anti-interleukin-2 receptor antibodies: basiliximab and daclizumab," <i>Nephrol Dial Transplant</i> , Vol. 16:1756-1760 (2001)		
↓	C5	Supplementary European Search Report for Application No. EP03786661, dated March 23, 2007		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Lynn Bristol/	Date Considered	10/30/2007
-----------------------	----------------	--------------------	------------



Used in Lieu of PTO/SB/08A/B
(Based on PTO 04-07 version)

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete If Known			
		Application Number	10/714,353-Conf. #6363		
		Filing Date	November 14, 2003		
		First Named Inventor	Janine SCHUURMAN		
		Art Unit	1643		
		Examiner Name	L. A. Bristol		
Sheet	1	of	2	Attorney Docket Number	GMI-059

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
LAB	C1	Baan, Carla C. et al., "Anti-CD25 Therapy Reveals the Redundancy of the Intragraft Cytokine Network After Clinical Heart Transplantation," <i>Transplantation</i> , Vol. 67(6):870-876 (1999)		
	C2	Baan, Carla C. et al., "Functional Responses of T Cells Blocked by Anti-CD25 Antibody Therapy During Cardiac Rejection," <i>Transplantation</i> , Vol. 69(3):331-336 (2000)		
	C3	Baan, Carla C. et al., "IL-15R α -Chain Expression During Anti-CD25 Treatment of Cardiac Allograft Recipients," <i>Transplantation Proceedings</i> , Vol. 34:3243-3245 (2002)		
	C4	Benito, José M. et al., "Quantitative Alterations of the Functionally Distinct Subsets of CD4 and CD8 T Lymphocytes in Asymptomatic HIV Infection: Changes in the Expression of CD45RO, CD45RA, CD11b, CD38, HLA-DR, and CD25 Antigens," <i>Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology</i> , Vol. 14(2):128-135 (1997)		
	C5	Engert, Andreas et al., "A Phase-I Study of an Anti-CD25 Ricin A-Chain Immunotoxin (RFT5-SMPT-dgA) in Patients With Refractory Hodgkin's Lymphoma," <i>Blood</i> , Vol. 89(2):403-410 (1997)		
	C6	Hartmann, Frank et al., "Radioimmunotherapy of Nude Mice Bearing a Human Interleukin 2 Receptor α -expressing Lymphoma Utilizing the α -emitting Radionuclide-conjugated Monoclonal Antibody ²¹² Bi-anti-Tac," <i>Cancer Research</i> , Vol. 54:4362-4370 (1994)		
	C7	Jakob, Thilo et al., "Stage-dependent Expression of CD7, CD45RO, CD45RA and CD25 on CD4-positive Peripheral Blood T-lymphocytes in Cutaneous T-cell Lymphoma," <i>Acta dermatovenereologica</i> , Vol. 76(1):34-36 (1996)		
	C8	Jones, Emma et al., "Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice," <i>Cancer Immunity</i> , Vol. 2(1):1-12 (2002)		
	C9	Kreitman, Robert J. et al., "Phase I Trial of Recombinant Immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) in Patients With Hematologic Malignancies," <i>Journal of Clinical Oncology</i> , Vol. 18(8):1622-1636 (2000)		
	C10	Krueger, James G. et al., "Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis," <i>J. Am. Acad. Dermatol.</i> , Vol. 43:448-458 (2000)		

Examiner Signature	/Lynn Bristol/	Date Considered	10/30/2007
--------------------	----------------	-----------------	------------

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/714,353-Conf. #6363	
			Filing Date	November 14, 2003	
			First Named Inventor	Janine SCHUURMAN	
			Art Unit	1643	
			Examiner Name	L. A. Bristol	
Sheet	2	of	2	Attorney Docket Number	GMI-059

LAB	C11	Kupiec-Weglinski, Jerzy W., "CD25-Targeted Therapy Revisited," <i>Transplantation</i> , Vol. 69(3):328-330 (2000)	
	C12	Laurie, Karen L. et al., "The role of CD4+CD25+ immunoregulatory T cells in the induction of autoimmune gastritis," <i>Immunology and Cell Biology</i> , Vol. 80:567-573 (2002)	
	C13	Mrowietz, Ulrich et al., "Treatment of Severe Psoriasis With Anti-CD25 Monoclonal Antibodies," <i>Arch. Dermatol.</i> , Vol. 136:675-676 (2000)	
	C14	Onizuka, Shozaburo et al., "Tumor Rejection by <i>in Vivo</i> Administration of Anti-CD25 (Interleukin-2 Receptor α) Monoclonal Antibody," <i>Cancer Research</i> , Vol. 59:3128-3133 (1999)	
	C15	Pfister, K. et al., "The <i>in vitro</i> anti-inflammatory effects of recombinant anti-CD25 immunotoxin on lamina propria T cells of patients with inflammatory bowel disease are not sufficient to cure experimental colitis in mice," <i>Int. J. Colorectal Dis.</i> , Vol. 17:77-84 (2002)	
	C16	Sakaguchi, Shimon et al., "Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance," <i>Immunological Reviews</i> , Vol. 182:18-32 (2001)	
	C17	Schnell, R. et al., "Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin," <i>Leukemia</i> , Vol. 14:129-135 (2000)	
	C18	Shevach, Ethan M., "CD4+CD25+ Suppressor T Cells: More Questions than Answers," <i>Nature Reviews</i> , Vol. 2:389-400 (2002)	
	C19	Shimizu, Jun et al., "Induction of Tumor Immunity by Removing CD25+CD4+ T Cells: A Common Basis Between Tumor Immunity and Autoimmunity," <i>The Journal of Immunology</i> , Vol. 163:5211-5218 (1999)	
	C20	Shimizu, Jun et al., "Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance," <i>Nature Immunology</i> , Vol. 3(2):135-142 (2002)	
	C21	Smith, Paul J. et al., "Characteristics of a Novel Deep Red/Infrared Fluorescent Cell-Permeant DNA Probe, DRAQ5, in Intact Human Cells Analyzed by Flow Cytometry, Confocal and Multiphoton Microscopy," <i>Cytometry</i> , Vol. 40:280-291 (2000)	
	C22	Steitz, Julia et al., "Depletion of CD25+ CD4+ T Cells and Treatment with Tyrosinase-related Protein 2-transduced Dendritic Cells Enhance the Interferon α -Induced, CD8+ T-Cell-dependent Immune Defense of B16 Melanoma," <i>Cancer Research</i> , Vol. 61:8643-8646 (2001)	
	C23	Szabolcs, P. et al., "Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease," <i>Bone Marrow Transplantation</i> , Vol. 30:327-329 (2002)	
	C24	van Besouw, N.M. et al., "Anti-CD25 Therapy Impairs Donor-Specific Th1 and Th2 Cytokine-Producing Peripheral Blood Cells After Clinical Heart Transplantation," <i>Transplantation Proceedings</i> , Vol. 34:2942-2943 (2002)	
	C25	Waldmann, Thomas A., "Anti-IL-2 Receptor Monoclonal Antibody (Anti-Tac) Treatment of T-Cell Lymphoma 8," <i>Important Advances in Oncology</i> , pp. 131-141 (1994)	
	C26	Waldmann, Thomas A. et al., "Radioimmunotherapy of Interleukin-2R α -Expressing Adult T-Cell Leukemia With Yttrium-90-Labeled Anti-Tac," <i>Blood</i> , Vol. 86(11):4063-4075 (1995)	
	C27	Wang, Hua et al., "TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice," <i>Nature Immunology</i> , Vol. 2(7):632-637 (2001)	
	C28	Woo, Edward Y. et al., "Regulatory CD4+CD25+ T Cells in Tumors from Patients with Early-Stage Non-Small Cell Lung Cancer and Late-Stage Ovarian Cancer," <i>Cancer Research</i> , Vol. 61:4766-4772 (2001)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Lynn Bristol/	Date Considered	10/30/2007
--------------------	----------------	-----------------	------------